Lymphoma

Latest News

Creating a Collaborative Edge Through the MZL Workshop
Creating a Collaborative Edge Through the MZL Workshop

February 12th 2025

Julie M. Vose, MD, MBA, answered questions about the significance and potential impact of MZL Workshop.

Data from the ECHELON-3 trial support the approval of the brentuximab vedotin combo in relapsed/refractory B-cell lymphoma.
FDA OKs Brentuximab Vedotin Combo in R/R Large B-Cell Lymphoma

February 12th 2025

Nodal Marginal Zone Lymphoma and Its Diagnostic Challenges
Nodal Marginal Zone Lymphoma and Its Diagnostic Challenges

February 11th 2025

In the phase 2 TRANSCEND FL trial, lisocabtagene maraleucel met its primary end point of overall response rate in patients with marginal zone lymphoma.
Liso-cel Demonstrates Significant Responses in Relapsed/Refractory MZL

February 10th 2025

Insights, Knowledge Gaps, and Priorities in Marginal Zone Lymphoma Research
Insights, Knowledge Gaps, and Priorities in Marginal Zone Lymphoma Research

February 10th 2025

More News